REG - GENinCode PLC - Partnership with Genesupport SA for the ROCA® Test

GenincodeAnnouncement

10/12/2024 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20241210:nRSJ4140Pa&default-theme=true

RNS Number : 4140P  GENinCode PLC  10 December 2024

GENinCode Plc

("GENinCode" or the "Company")

 

GENinCode partners with Genesupport SA for the ROCA® Test in Switzerland

Ovarian cancer surveillance using the ROCA Test to be made available to
individuals across Switzerland

 

Oxford, UK. GENinCode Plc (AIM: GENI), the predictive genetics company focused
on the prevention of cardiovascular disease ("CVD") and risk of ovarian cancer
("OC"), announces its partnership with Genesupport SA, part of the Sonic
Switzerland network of laboratories, to enable country-wide access to the
ROCA® Test.

 

In March 2024, the ROCA Test received a National Institute for Health and Care
Excellence ("NICE") recommendation as the preferred test for OC surveillance
in individuals at high risk of ovarian cancer who wish to defer risk-reducing
surgery.(1) Based on this milestone, Genesupport SA will make the ROCA Test
available through all Sonic Switzerland diagnostic and genetic companies,
including Genesupport, Medigenome Medisupport, Medica, Medisyn, and Dr Risch.
These companies cover all major Swiss cities (Geneva, Lausanne, Bern and
Zurich), and regional centers (e.g. St. Gallen, Zug, Lucerne, Lugano/Locarno).
Genesupport is also affiliated with the major tumour centres and hospital
groups across the country (e.g. Hirslanden and Swiss Medical Network).
Genesupport will offer the test under the ROCA brand in Switzerland, to women
who are BRCA positive and have not undertaken risk reducing surgery, with the
test supporting an eligible population of more than 11,000 women at high risk
of OC.

 

Each year there are over 300,000 new cases of OC globally and over half of
those will die from the disease. The risk of developing OC is particularly
high in individuals who inherit a known pathogenic variant in certain genes
such as BRCA1 or BRCA2.(2) Such mutations occur in up to 0.4% of the general
population and up to 3% of individuals of Jewish descent. Identifying such
individuals through genetic testing will allow healthcare professionals to
better mitigate that risk through preventive surgery and/or surveillance.

 

The ROCA Test uses a proprietary algorithm to calculate a woman's individual
OC risk based on several clinical factors including age and accumulating
Cancer Antigen 125 (CA-125) blood test results. The ROCA Test has many years
of clinical evaluation through prospective studies(3) which have proven its
high accuracy and ability to detect OC earlier. Earlier detection improves
treatment outcomes.

 

Matthew Walls, Chief Executive Officer of GENinCode Plc, said: "We are
delighted to partner with Genesupport to allow access to the ROCA Test in the
Swiss market. After many years of academic and corporate investment, the ROCA
test is now lifting the standard of care for patients at high risk of familial
ovarian cancer who decide to defer preventive surgery. Surveillance using the
ROCA test will help individuals feel more supported while they start or build
their families or until they are ready to undertake surgery."

 

Bernard Conrad, Chief Medical Officer of Genesupport, said: "Offering the ROCA
Test throughout the Sonic Switzerland network synergises well with our other
services in the field of genetic testing and women's health. Based on the
evidence that has accrued over many years, the ROCA Test is recognised as the
best in class and is an important test to be able to offer women who face
difficult choices in managing their familial ovarian cancer risk."

 

 

(1) Project information | Ovarian cancer; identifying and managing familial
and genetic risk |Guidance|NICE

(2) BRCA1, BRCA2, MLH1, MSH2, MSH6, RAD51C, RAD51D, BRIP1 and PALB2

(3 )Rosenthal, AN, et al. J. Clin. Oncol. 35(13): 1411-1420, 2017; Skates,
SJ, et al. Clin. Cancer Res. 23(14): 3628- 3637, 2017; Philpott, S et al. J
Med Genet. 60(5):440-449, 2023.

 

For more information visit www.genincode.com (http://www.genincode.com)

 

 GENinCode Plc                                         www.genincode.com (http://www.genincode.com) or via Walbrook PR
 Matthew Walls, CEO

 Cavendish Capital Markets Limited                                             Tel: +44 (0)20 7397 8900
 Giles Balleny / Dan Hodkinson (Corporate Finance)

 Nigel Birks (Life Sciences Specialist Sales)

 Ondraya Swanson (Corporate Broking)

 Dale Bellis / Michael Johnson (Sales)

 Walbrook PR Limited        Tel: 020 7933 8780 or genincode@walbrookpr.com
                            (mailto:genincode@walbrookpr.com)
 Anna Dunphy / Louis Ashe-Jepson / Phillip Marriage

 

About GENinCode

GENinCode Plc is a UK based company specialising in genetic risk assessment of
cardiovascular disease and risk of ovarian cancer, two of the leading causes
of death and disability worldwide.

 

GENinCode operates business units in the UK, in the United States through
GENinCode U.S. Inc and in Europe through GENinCode S.L.U.

 

GENinCode predictive technology provides patients and physicians with globally
leading preventive care and treatment strategies. GENinCode CE marked
invitro-diagnostic molecular tests combine clinical algorithms and
bioinformatics to provide advanced patient risk assessment to predict disease
onset.

 

About Genesupport SA

Genesupport SA offers a complete healthcare service in the field of prenatal,
paediatric and adult human genetics: it has multidisciplinary competence
combining molecular genetics, conventional and molecular cytogenetics, and
cytogenomics. Genesupport's genetics centre occupies two sites, in Lausanne
and Geneva, Switzerland.

 

Along with its medical genetics work, Genesupport offers customised genetic
counselling, provided by Swiss Medical Association (FMH) specialists in
medical genetics and qualified counsellors trained in medical genetics.
Genesupport also provides DNA sequencing and bioinformatics services for
researchers worldwide. This work is undertaken in its "Life Science" division
under the Fasteris (https://www.fasteris.com/en-us)  brand name.

 

About Ovarian Cancer

Ovarian cancer is a disease that originates in the ovaries, or in the related
areas of the fallopian tubes and the peritoneum. Women have two ovaries that
are located in the pelvis, one on each side of the uterus. The ovaries make
female hormones and produce eggs for reproduction. Women have two fallopian
tubes that are a pair of long, slender tubes on each side of the uterus. Eggs
pass from the ovaries through the fallopian tubes to the uterus. The
peritoneum is the tissue lining that covers organs in the abdomen.

 

Ovarian cancer ranks fifth in cancer deaths among women, accounting for more
deaths than any other cancer of the female reproductive system. The World
Cancer Research Fund International estimates for ovarian cancer in the
worldwide are:

 

·      Approximately 324,603 women will receive a new diagnosis of
ovarian cancer per year.

·      Approximately 206,956 women will die from ovarian cancer.

 

A woman's risk of ovarian cancer during her lifetime is about one in 56. It is
more common in white women than African American women. The risk of ovarian
cancer increases with age, with most cases occurring in women over 60.
However, having a family history of ovarian cancer or being of Ashkenazi
Jewish descent may point to an individual carrying a genetic variant in one of
several genes e.g. in BRCA1 and BRCA2 that are known to increase ovarian
cancer risk. Up to 20% of ovarian cancer is due to genetic causes.

 

When ovarian cancer is found in its early stages, long term survival is
improved due to more complete tumour resection and more effective treatment.
Ovarian cancer is difficult to diagnose through symptom presentation, as the
symptoms are vague and present very often only when the cancer has spread
beyond the ovaries.

 

The ROCA Test offers surveillance for women with a BRCA1 or BRCA2 mutation who
are not ready to undertake risk reducing surgery.

 

ROCA® (Risk of Ovarian Cancer Algorithm) is a registered trademark of
GENinCode Plc in the UK, European Union and in the United States

 

To read more about the ROCA Test, see www.therocatest.co.uk
(http://www.therocatest.com)

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCFSAEFUELSEIE